INTRODUCTION AND OBJECTIVES:
Patients with medically refractory erectile dysfunction (ED) frequently have cardiovascular risk factors requiring antithrombotics (anticoagulation and/or antiplatelets) at the time of inflatable penile prosthesis (IPP) surgery. Discontinuation of antithrombotics prior to surgery is associated with increased myocardial infarction and cerebrovascular accident risk. Limited data are available on perioperative morbidity associated with continuation of antithrombotics at time of IPP placement. We sought to evaluate the outcomes of continuation of antithrombotics at time of IPP surgery.
METHODS: We retrospectively reviewed clinical and operative records of men undergoing IPP placement at our institution. In this series, the device was left inflated at 60-80% and a mummy wrap was performed. Detailed information was obtained related to perioperative antithrombotic management and postoperative outcomes. Statistical analysis was performed to evaluate for differences in scrotal drain output, hematoma formation rate, and post-operative morbidity among patients who continued versus held antithrombotics.
RESULTS: 70 patients (mean age 65 years) underwent IPP placement at our institution from July 2017 through May 2018. Of these men, 40 (57%) reported baseline use of antithrombotics and make up the current study cohort. Twenty-seven of the 40 (68%) continued antithrombotics through IPP placement, including aspirin 81mg (n and combination therapy (N[6) . On univariate analysis, no statistically significant difference in post-operative day zero drain output was identified between patients who continued versus held antithrombotics at the time of surgery (72.6 mL vs 73.4 mL; p[0.94). Three patients (4%), developed self-resolving hematomas at 6 week follow up. Of these three patients, one was not on antithrombotics at baseline, one continued aspirin 81mg and held Xarelto, and one continued aspirin 81mg. No difference in hematoma formation was identified in patients who continued on aspirin, apixaban, clopidogrel, warfarin, or combination therapy compared to patients off of antithrombotics (all p>0.05). 13 of 40 patients (32%) held antithrombotics at time of surgery with 2 of 13 (15%) experiencing a post-operative cardiovascular event.
CONCLUSIONS: In a small operative series, continuing antithrombotics at the time of IPP placement did not result in statistically higher scrotal drain output or rate of hematomas compared to those who held antithrombotics. Given the potential complications of holding antithrombotics in a high-risk population, these data suggest a practice of continuing antithrombotics at the time of IPP surgery and require further validation.
Source of Funding: none

MP27-05 PENILE IMPLANT SURGERY DOES NOT REDUCE PENILE SIZE; A PROSPECTIVE STUDY OF 122 PATIENTS FOLLOWED UP FOR TWO YEARS
Mohamad Habous*, Jedda, Saudi Arabia; Simone Giona, Camberley, United Kingdom; Osama Abdelwahab, Jedda, Saudi Arabia; Osama Laban, Tabouk, Saudi Arabia; Saleh Binsaleh, Riyadh, Saudi Arabia; John Mulhall, New York, NY; Usama Kamil, Alaa Tealab, Jedda, Saudi Arabia; Gordon Muir, David Ralph, London, United Kingdom INTRODUCTION AND OBJECTIVES: A common cause of patient dissatisfaction after penile prosthesis implantation (PPI) is caused by the patient believing the penis has been shortened.This prospective study aimed to investigate the correlation between stretched penile dimensions measured preoperatively and erect postoperative penile dimensions after 6,12 and 24 months.
METHODS: Consecutive PPI were assessed in a highvolume center from January 2015 until July 2018. Standardized measurements of stretched penile length and girth were performed in theatre preoperatively and at the end of surgery with the penis in the erect position. The erect penile length and girth was then again measured at 6,12 and 24 months follow up. A special questionnaire containing 5 questions was used for this study and completed at each visit. The first three questions detailed the patient perception of penile size post-operatively, being increased, decreased, or same size. The 4th question a Likert scale from 1-5 about overall satisfaction and the last questions if he recommends the operation to a friend. Microsoft Excel and SPSS were used for database and statistical analysis RESULTS: 122 patients had complete data and were included in the analysis. An inflatable prosthesis was used in 48(39%) and a malleable in 74(61%) patients. The median age was 56 and the mean BMI was 30. Overall, there was a statistically significant but marginal increase in length at 6/12 months follow-up of 0.09 cm (P[0.002) when compared to immediate post-operative size. At 12 months the increase in length was 0.26cm (P<<0.05). At 24 months this figure increases again to 0.36cm remaining significant (P[0.035). When stratified for malleable (MPP) versus inflatable (IPP), there was a small but statistically significant steady decrease in girth at 6 and 12 and 24 months for MPP of 0.08, 0.29 and 0.25 cm respectively (P<0.05).There was no reduction in girth in the IPP. The subjective and objective measurements were different: 45.1% (55) felt they had a smaller penis at 1 year but actually only 12.3% (15) had an objective reduction in either girth or length, and in 25.4% (31) there was an objective increase (Figure 1) . The majority of patients e364 THE JOURNAL OF UROLOGY Ò Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
